ArticleFrontiers in pharmacology2025
A novel strategy for identifying hepatotoxic constituents in traditional Chinese medicine using dose-normalized intracellular accumulation as a cytotoxicity indicator: a case study of Jinlingzi San.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Herb-induced liver injury associated with traditional Chinese medicine (TCM) has increasingly attracted scientific attention. However, the rapid and effective methods for elucidating the material basis of hepatotoxicity in TCM are still lacking. This study developed a strategy based on the use of dose-normalized intracellular accumulation as a cytotoxicity indicator to identify key hepatotoxic components in TCM. Methods: Jinlingzi San (JLZS) composed of Fructus Toosendan (FT) and Rhizoma Corydalis (RC) was used as a model sample in this study. Hepatotoxicity was evaluated through both in vivo (14-day continuous gavage administration in rats) and in vitro (24-hour co-incubation with L-02 cells) models. Chemical components in JLZS extract and those accumulated in L-02 cells were identified using LC-MS/MS. The intracellular accumulations of multiple components after exposing L-02 cells to the extracts of JLZS, FT and RC were determined. Results: JLZS administration resulted in subacute liver injury in rats and demonstrated cytotoxicity to L-02 cells. Seven analytes (coptisine, tetrahydrocoptisine, berberine, jatrorrhizine, palmatine, dehydrocorydaline and toosendanin) were identified in cell lysates following incubation with JLZS. Coptisine and berberine were regarded as the main potential hepatotoxic components in JLZS for its highest dose-normalized intracellular accumulation and the strongest cytotoxicity. In addition, the intracellular accumulations of coptisine and berberine were lower in the JLZS group compared to the RC group alone. Discussion: The findings suggest that dose-normalized intracellular accumulation serves as a reliable indicator for identifying hepatotoxic constituents in TCM. The observed reduction in intracellular accumulation of coptisine and berberine in the JLZS formulation compared to RC alone maybe reflect the scientific meaning of detoxicity by compatibility with FT and RC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.